Latest news with #STC-1010
Business Wire
4 days ago
- Business
- Business Wire
Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking
LISBON, Portugal--(BUSINESS WIRE)--Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus' lead candidate for colorectal cancer. 'This collaboration has enabled us to assess the highly representative and scalable 3D model into our SGC platform. It's a major step forward in our ability to assess potency and accelerate the development of STC-1010 and future candidates.' Benoit Pinteur Share Funded through the EUROSTARS program, the collaboration led to vitrified 3D colorectal cancer spheroids using tumor cell lines co-cultured with fibroblasts. The vitrification method preserves morphology, stromal integrity, and viability after thawing, enabling realistic evaluation of STC-1010's therapeutic potential under conditions mimicking in vivo human tumors. Previous studies showed that STC-1010 antigens were effectively processed by monocyte-derived dendritic cells (mMo-DCs), activating CD8+ T cells. These T cells induced apoptosis in both 2D and 3D colorectal cancer models and released anti-tumor cytokines (IFNγ and Granzyme B). These data reinforce the therapeutic potential of STC-1010. ' This collaboration has enabled us to assess the highly representative and scalable 3D model into our SGC platform. It's a major step forward in our ability to assess potency and accelerate the development of STC-1010 and future candidates.' Benoit Pinteur, CSO of Brenus Pharma. ' We are proud to support Brenus with our cryopreserved 3D tumor models. This work illustrates how advanced in vitro systems can bring immunotherapies closer to clinical reality.' Jan Lichtenberg, CEO of InSphero. About Brenus Pharma Brenus Pharma unlocks the potential of immuno-oncology by generating first-in-class immunotherapies that initiate a multi-specific in vivo immune response against tumors. Their proprietary 'off-the-shelf' Stimulated-tumor-Ghost-Cells (SGC) platform mimics patients' tumor cells and makes them visible to the immune system to anticipate, target, and destroy these cells as they appear. Brenus aims to shift the oncology paradigm by making patients active participants in their treatment.
Business Wire
07-05-2025
- Business
- Business Wire
AACR 2025: Brenus Pharma Presents Late-breaking Preclinical Data on its 'off-the-shelf' Next-generation Vaccine-based Immunotherapy Candidate, STC-1010, Now Moving to Clinic
LYON, France--(BUSINESS WIRE)--Brenus Pharma, a French clinical-stage biotechnology company, presented new preclinical data on its lead immunotherapy candidate, STC-1010, during the Late-Breaking Research: Immunology 3 session at the AACR Annual Meeting 2025, held April 25–30 in Chicago, IL. 'Immunotherapy was clearly a central focus at AACR 2025, with growing recognition across the scientific community that cancer vaccines are now a promising strategy for both treatment and prevention.' said George Alzeeb, PhD, Innovation Manager at Brenus Ph Share The data highlight advances from Brenus Pharma's proprietary Stimulated-Tumor-Ghost Cell (SGC) platform, a next-generation precision immuno-oncology approach showcasing its potential to initiate a robust anti-tumor response in colorectal cancer—a major unmet need in solid tumors. Key findings demonstrate the reproducibility of STC-1010's anti-tumor profile across multiple manufacturing batches and preclinical models (in vivo, in ovo, ex vivo) including those modified to be resistant to current immunotherapies. Dendritic cells showed increased antigen presentation and activation of CD8⁺ T cells with STC-1010, resulting in significant tumor cell apoptosis (tumor killing) and reduced metastasis. 'Immunotherapy was clearly a central focus at AACR 2025, with growing recognition across the scientific community that cancer vaccines are now a promising strategy for both treatment and prevention.' said George Alzeeb, PhD, Innovation Manager at Brenus Pharma. 'We're proud to be part of this momentum and look forward to the next steps.' Title: ' Preclinical efficacy of an innovative therapeutic cancer vaccine: a new era for immunotherapy ' LB383 – Session: Late-Breaking Research: Immunology 3 [ poster ] Authors: George Alzeeb¹, Iseulys Richert¹, Corentin Richart², Paul Marteau³, Lionel Chalus¹, Marion Brun¹, Yan Wan⁴, Corinne Tortorelli¹, Benoit Pinteur¹, Paul Bravetti¹, Céline Gongora⁵, Antoine Italiano⁶, François Ghiringhelli⁷ ¹Brenus Pharma – ²ICMUB UMR CNRS 6302 – ³Explicyte – ⁴Inovotion – ⁵INSERM U1194 – ⁶Institut Bergonié – ⁷INSERM UMR1231 About us: Brenus' off-the-shelf platform empowers immune cells in vivo to fight cancer by mimicking cancer nature and making it visible to the immune system. We are developing a solid tumor pipeline leveraging our proprietary next-generation precision platform and making patient once again actor in their treatment.
